HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Aden Colony (Arabic: مُسْتْعَمَرَةْ عَدَنْ, romanised: Musta'marat 'Adan) was a crown colony of the United Kingdom from 1937 to 1963 located in the southern part of modern-day Yemen. It consisted of the port city of Aden and also included the outlying islands of Kamaran, Perim and the Khuria Muria archipelago with a total area of 192 km2 (74 sq mi). Initially a key port for the British East India Company, it was annexed by the British in 1839 to secure maritime routes and prevent piracy in the Arabian Sea. Its strategic position at the entrance to the Red Sea made it a vital stopover for ships traveling between Europe, India, and the Far East, especially after the opening of the Suez Canal in 1869. Aden quickly became a major coaling station and transit hub for British shipping, and its significance to the British Empire grew throughout the 19th and early 20th centuries. Prior to 1937, Aden had been governed as part of British India (originally as the Aden Settlement subordinate to the Bombay Presidency, and then as a Chief Commissioner's province). On 1 April 1937, Aden was separated from British India to become a Crown colony under the Government of India Act 1935, consisting of the city of Aden and its surrounding areas. The colony experienced rapid development due to its thriving port, but it was also marked by growing civil unrest. Economic inequality, labour strikes, and the rise of Arab nationalism contributed to increasing tensions, which were intensified by the anti-colonial sentiment in the Middle East.
Retinol is chemically unstable in topical formulations and is sensitive to factors such as light, oxygen, heat, and heavy metals; formulation approaches including retinol derivatives, antioxidants, chelating agents, and lipid-based or nanoformulation systems have been investigated to improve stability, tolerability, and skin delivery. A common side effect of topical retinoid therapy is "retinoid dermatitis", irritation or reaction characterized by erythema, scaling, dryness, and pruritis. Topical retinol has been regulated as a cosmetic ingredient in the European Union and UK since November 2025; under Commission Regulation 2024/996, retinol was limited to a maximum of 0.05% retinol equivalent in body lotion and 0.3% in other leave-on and rinse-off products, with mandatory labelling.
=== MHC-I === MHC-I heavy chains may work as chaperones with the aid of the calnexin-calreticulin complex in the ER. In addition to this, β2-microglobulin (β2m) is attached to the heavy chains of the heterodimers and as a whole they act as receptors for antigenic peptides. When MHC-I chains are empty, they are recruited by calreticulin and form a transient PLC. Tapasin regularly plays a role in the stabilization of MHC-I. Only after MHC-I heterodimers are deployed for peptide proofreading or editing, stable pMHC-I (peptide-MHC-I) complexes are released to the cell surface for recognition and destruction of virus-infected or malignantly neoplastic cells. In general, each individual organism owns a collection of six MHC-I molecules (three from each parent). Thus, in autoimmune emergencies, compatible donors are relatives who own a similar collection of MHC-I molecules, apart from those of the recipient.
The ability of yeast to convert sugar into ethanol has been harnessed by the biotechnology industry to produce ethanol fuel. The process starts by milling a feedstock, such as sugar cane, field corn, or other cereal grains, and then adding dilute sulfuric acid, or fungal alpha amylase enzymes, to break down the starches into complex sugars. A glucoamylase is then added to break the complex sugars down into simple sugars. After this, yeasts are added to convert the simple sugars to ethanol, which is then distilled off to obtain ethanol up to 96% in purity. Saccharomyces yeasts have been genetically engineered to ferment xylose, one of the major fermentable sugars present in cellulosic biomasses, such as agriculture residues, paper wastes, and wood chips. Such a development means ethanol can be efficiently produced from more inexpensive feedstocks, making cellulosic ethanol fuel a more competitively priced alternative to gasoline fuels.
Sources: en.wikipedia.org
dimer A molecular aggregate consisting of two subunits. The term is often used to describe a protein complex composed of two proteins, either the same protein (a homodimer) or different proteins (a heterodimer); or to an individual protein composed of two polypeptides. Compare monomer, trimer, and tetramer.
Proteins with GO terms related to polysaccharide binding and processing were enriched for serine and threonine in their LCRs. Proteins with GO terms related to RNA binding and processing were enriched for arginine in their LCRs. Proteins with GO terms related to DNA binding and processing were especially enriched for lysine, but also for glycine, tyrosine, phenylalanine and glutamine in their LCRs. Proteins with GO terms related to metal binding and more specifically to cobalt or nickel-binding were enriched mostly for histidine but also for aspartate in their LCRs. Proteins with GO terms related to protein folding were enriched for glycine, methionine and phenylalanine in their LCRs. Based on the above observations and analyses, a Neural Network webserver named LCR-hound has been developed to predict LCRs and their function.
If there are to be multiple ICP-MS instruments running for long periods of time, then it will most likely be beneficial for the laboratory to install a bulk or micro bulk argon tank which will be maintained by a gas supply company, thus eliminating the need to change out tanks frequently as well as minimizing loss of argon that is left over in each used tank as well as down time for tank changeover. Helium can be used either in place of, or mixed with, argon for plasma generation. Helium's higher first ionisation energy allows greater ionisation and therefore higher sensitivity for hard-to-ionise elements. The use of pure helium also avoids argon-based interferences such as ArO. However, many of the interferences can be mitigated by use of a collision cell, and the greater cost of helium has prevented its use in commercial ICP-MS.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.